White Paper: Valuation of Your Early Drug Candidate

A "No-Formulas" Tour of Valuation

Biotech companies seek partnerships (collaborations, licensing deals, joint ventures, etc) to advance their drug candidates and raise funds. They frequently ask "How much is this drug candidate worth to a partner?"

Early drug candidates, due to numerous factors such as long development timelines before the value is realized, many questions yet unanswered, ever-changing market conditions and regulatory requirements, and the high risk of technical failure can be more difficult to value.

In this new white paper, author Linda Pullan reviews the different techniques, key variables, and characteristics of what makes a drug candidate more valuable to a partner. Find out how valuation gets translated to deal terms and get a clear, conceptual framework for your drug's valuation.

 

ABOUT SHAREVAULT:

ShareVault’s secure document sharing solution gives pharmaceutical and biotechnology organizations the confidence to simply and securely share sensitive documents with third parties during due diligence, product development, technology transfers, fundraising, partnering, collaborative research and other activities that require the highest level of document control and security.

Compared to consumer-grade solutions, ShareVault virtual data rooms offer many features that give you control and document intelligence with the highest level of document protection and monitoring available. Learn more.

Download
the white paper